source
- STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rateA combination of pancreatic cancer drugs from Tango Therapeutics and Revolution Medicines led to a strong response rate in an early-stage trial.STAT · 1mo ago↗ source
- Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront dealIncyte plans to spend $1.25 billion upfront to buy Star Therapeutics' subsidiary Vega Therapeutics and its Phase 3 bleeding disorder candidate, the companies said Monday. The deal package also incl…Endpoints · 1mo ago↗ source
- Takeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appealTakeda has updated its financial results to reflect costs it could incur after losing an antitrust lawsuit concerning its laxative drug Amitiza. In May, the US District Court in Massachusetts ruled…